ENDONOVO THERAPEUTICS, INC. (ENDV) Gross margin 2013–2022
ENDONOVO THERAPEUTICS, INC. (ENDV) gross margin by fiscal year — reported gross profit divided by reported revenue.
92.6%FY2022 · since FY2013: 38.9% → 92.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2022 | 92.6% | +13.1 pp |
| FY2021 | 79.5% | +18.9 pp |
| FY2020 | 60.6% | -9.3 pp |
| FY2019 | 69.9% | -14.6 pp |
| FY2018 | 84.5% | — |
| FY2015 | 49.3% | +13.3 pp |
| FY2014 | 36.0% | -2.9 pp |
| FY2013 | 38.9% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More ENDV financial trends
ENDV RevenueENDV Net incomeENDV Net marginENDV Gross profitENDV Operating incomeENDV Operating marginENDV Operating cash flowENDV Free cash flowENDV Capital expendituresENDV Return on equityENDV Stock buybacksENDV Dividends paidENDV Total assetsENDV Total liabilitiesENDV Shareholders’ equityENDV overview →